Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2018	Mar. 05, 2019	Jun. 29, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	CUMBERLAND PHARMACEUTICALS INC
Entity Central Index Key	0001087294
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		15,447,413
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 58,282,085

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 27,938,960	$ 45,412,868
Marketable securities	8,290,679	4,672,476
Accounts receivable, net of allowances	7,844,249	8,395,112
Inventories, net	12,078,343	6,737,848
Prepaid and other current assets	2,963,806	3,466,541
Total current assets	59,116,037	68,684,845
Property and equipment, net	771,213	528,882
Intangible assets, net	33,655,099	21,444,545
Goodwill	784,000	0
Deferred tax assets, net	87,210	87,210
Other assets	2,531,309	2,486,830
Total assets	112,693,868	93,232,312
Current liabilities:
Accounts payable	11,093,297	8,979,929
Other current liabilities	16,710,927	8,714,814
Total current liabilities	27,804,224	17,694,743
Revolving line of credit	20,000,000	9,800,000
Other long-term liabilities	9,319,143	1,815,968
Total liabilities	57,123,367	29,310,711
Commitments and contingencies
Shareholders’ equity:
Common stock – no par value; 100,000,000 shares authorized; 15,723,075 and 16,074,176 shares issued and outstanding as of December 31, 2017 and 2016, respectively	51,098,613	52,410,941
Retained earnings	4,746,154	11,709,222
Total shareholders’ equity	55,844,767	64,120,163
Noncontrolling interests	(274,266)	(198,562)
Total equity	55,570,501	63,921,601
Total liabilities and equity	$ 112,693,868	$ 93,232,312

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, no par value (dollars per share)	$ 0	$ 0
Common stock, number of shares authorized	100,000,000	100,000,000
Common stock, number of shares issued	15,723,075	16,074,176
Common stock, number of shares outstanding	15,723,075	16,074,176

Consolidated Statements of Income and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Revenues	$ 40,741,765	$ 41,150,131	$ 33,025,560
Costs and expenses:
Cost of products sold	7,378,095	7,370,585	5,958,660
Selling and marketing	20,258,307	21,492,937	14,553,481
Research and development	7,320,797	3,901,365	3,190,700
General and administrative	10,405,872	10,030,370	8,561,811
Amortization	2,769,466	2,436,222	2,194,039
Total costs and expenses	48,132,537	45,231,479	34,458,691
Operating income (loss)	(7,390,772)	(4,081,348)	(1,433,131)
Interest income	564,484	299,326	204,661
Interest expense	(195,848)	(92,904)	(106,392)
Income (loss) before income taxes	(7,022,136)	(3,874,926)	(1,334,862)
Income tax (expense) benefit	(16,636)	(4,174,889)	330,924
Net income (loss)	(7,038,772)	(8,049,815)	(1,003,938)
Net loss at subsidiary attributable to noncontrolling interests	75,704	71,182	59,255
Net income (loss) attributable to common shareholders	$ (6,963,068)	$ (7,978,633)	$ (944,683)
Earnings (loss) per share attributable to common shareholders:
Basic (in USD per share)	$ (0.45)	$ (0.50)	$ (0.06)
Diluted (in USD per share)	$ (0.45)	$ (0.50)	$ (0.06)
Weighted-average common shares outstanding:
Basic (in shares)	15,614,052	15,911,577	16,236,525
Diluted (in shares)	15,614,052	15,911,577	16,236,525
Comprehensive income (loss) attributable to common shareholders	$ (6,963,068)	$ (7,978,633)	$ (944,683)
Net loss at subsidiary attributable to noncontrolling interests	75,704	71,182	59,255
Total comprehensive income (loss)	(7,038,772)	(8,049,815)	(1,003,938)
Product
Revenues:
Revenues	40,200,832	40,376,563	32,478,185
Other
Revenues:
Revenues	$ 540,933	$ 773,568	$ 547,375

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ (7,038,772)	$ (8,049,815)	$ (1,003,938)
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:
Depreciation and amortization expense	2,982,703	2,647,753	2,396,908
Deferred tax expense	81,886	4,206,753	619,580
Share-based compensation	1,364,698	1,115,063	852,102
Share-based compensation (foundation contribution)	0	372,500	0
Excess tax (benefit) expense derived from exercise of stock options	(81,886)	(91,109)	1,026,413
Noncash interest expense	99,883	77,911	84,539
Noncash investment gains	(168,440)	(52,012)	(74,015)
Net changes in assets and liabilities affecting operating activities:
Accounts receivable	550,863	(1,064,985)	(1,253,007)
Inventories	460,505	(1,366,118)	(1,101,586)
Prepaid, other current assets and other assets	712,149	(1,074,369)	(1,556,282)
Accounts payable and other current liabilities	4,308,706	2,307,617	191,901
Other long-term liabilities	(159,558)	413,097	386,863
Net cash provided by (used in) operating activities	3,112,737	(557,714)	569,478
Cash flows from investing activities:
Additions to property and equipment	(455,569)	(275,960)	(130,872)
Additions to intangible assets	(3,819,486)	(1,213,110)	(2,000,226)
Cash paid for acquisition	(20,000,000)	0	0
Proceeds from sale of marketable securities	16,663,232	13,381,061	4,489,111
Purchases of marketable securities	(20,112,995)	(2,379,414)	(5,473,092)
Net cash provided by (used in) investing activities	(27,724,818)	9,512,577	(3,115,079)
Cash flows from financing activities:
Borrowings on line of credit	56,000,000	24,500,000	2,400,000
Repayments on line of credit	(45,800,000)	(18,800,000)	0
Repurchase of common shares	(2,879,426)	(3,724,375)	(2,520,715)
Payments of deferred equity offering costs	(383,310)	(27,950)	0
Exercise of stock options	200,909	0	0
Excess tax (expense) benefit derived from exercise of stock options	0	0	(1,026,413)
Net cash provided by (used in) financing activities	7,138,173	1,947,675	(1,147,128)
Net increase (decrease) in cash and cash equivalents	(17,473,908)	10,902,538	(3,692,729)
Cash and cash equivalents, beginning of year	45,412,868	34,510,330	38,203,059
Cash and cash equivalents, end of year	27,938,960	45,412,868	34,510,330
Net cash paid (refunded) during the year for:
Interest	95,965	14,993	21,853
Income taxes	15,441	18,000	(8,359)
Noncash investing and financing activities:
Change in unpaid invoices for purchases of intangibles	(539,467)	(513,481)	(1,179,394)
Deferred offering costs included in accounts payable and other accrued expenses	0	97,254	0
Non cash increase in liabilities related to acquisition (see Note 3)	$ 14,034,000	$ 0	$ 0

Consolidated Statements of Equity - USD ($)	Total	Common stock	Retained earnings	Noncontrolling interest
Equity, balance at Dec. 31, 2015	$ 76,819,783	$ 57,338,294	$ 19,549,614	$ (68,125)
Equity, common shares outstanding at Dec. 31, 2015		16,379,501
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss) attributable to common shareholders	(944,683)		(944,683)
Net loss at subsidiary attributable to noncontrolling interests	(59,255)			(59,255)
Net income (loss)	(1,003,938)
Share-based compensation, amount	852,102	$ 852,102
Share-based compensation, shares		223,987
Exercise of options and related tax benefit	(1,026,413)	$ (1,026,413)
Exercise of options and related tax benefit, shares		3,409
Repurchase of common shares	(2,520,715)	$ (2,520,715)
Repurchase of common shares, shares		(529,312)
Equity, balance at Dec. 31, 2016	73,120,819	$ 54,643,268	18,604,931	(127,380)
Equity, common shares outstanding at Dec. 31, 2016		16,074,176
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss) attributable to common shareholders	(7,978,633)		(7,978,633)
Net loss at subsidiary attributable to noncontrolling interests	(71,182)			(71,182)
Net income (loss)	(8,049,815)
Share-based compensation, amount	1,115,063	$ 1,115,063
Share-based compensation, shares		146,275
Charitable contribution of shares, shares		50,000
Exercise of options and related tax benefit	372,500
Repurchase of common shares	(3,719,890)	$ (3,719,890)
Repurchase of common shares, shares		(547,376)
Equity, balance at Dec. 31, 2017	$ 63,921,601	$ 52,410,941	11,709,222	(198,562)
Equity, common shares outstanding at Dec. 31, 2017	16,074,176	15,723,075
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Cumulative effect from change in accounting principle (Note 12)	$ 1,082,924		1,082,924
Net income (loss) attributable to common shareholders	(2,379,239)
Equity, balance at Dec. 31, 2017	$ 63,921,601	$ 52,410,941	11,709,222	(198,562)
Equity, common shares outstanding at Dec. 31, 2017	16,074,176	15,723,075
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net income (loss) attributable to common shareholders	$ (6,963,068)		(6,963,068)
Net loss at subsidiary attributable to noncontrolling interests	(75,704)			(75,704)
Net income (loss)	(7,038,772)
Share-based compensation, amount	1,364,698	$ 1,364,698
Share-based compensation, shares		170,759
Proceeds from sale of common stock, net of offering costs	200,909	$ 200,909
Proceeds from the sale of common stock, net of offering costs, shares		30,704
Repurchase of common shares	(2,877,935)	$ (2,877,935)
Repurchase of common shares, shares		(443,041)
Equity, balance at Dec. 31, 2018	$ 55,570,501	$ 51,098,613	$ 4,746,154	$ (274,266)
Equity, common shares outstanding at Dec. 31, 2018	15,723,075	15,481,497

Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2018

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Valuation and Qualifying Accounts

Years ended December 31, 2018, 2017 and 2016


Description	Balance at beginning of period		Charged to costs and expenses			Charged to other accounts		Deductions			Balance at end of period

Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:
For the years ended December 31:
2016	$	381,240	$	3,755,804		$	—	$	(3,687,185)	(1)	$	449,859
2017	449,859		5,066,526			—		(5,008,851)		(1)	507,534
2018	507,534		6,286,581			—		(5,800,775)		(1)	993,340

Valuation allowance for deferred tax assets:
For the years ended December 31:
2016	$	185,497	$	203,003		$	—	$	—		$	388,500
2017	388,500		(665,039)		(2)	15,908,774		—			15,632,235
2018	15,632,235		1,749,817			—		—			17,382,052

(1) Composed of actual returns and credits for chargebacks and cash discounts.

(2) Amount includes $4,202,854 related to increase in the valuation allowance during the year, net of $4,867,893 related to the revaluation of deferred income tax balances for new rates under the Tax Act.

Organization	12 Months Ended
Organization	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Cumberland Pharmaceuticals Inc. and its subsidiaries ("Cumberland," the "Company," or as used in the context "our" or "we") is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs. Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States. In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace. The Company’s ownership in CET is 80%. In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET. This financing included an investment of approximately $1.0 million from Gloria Pharmaceuticals Co., Ltd. (“Gloria”). As a result, Gloria received shares in CET and joined the CET ownership group. As noted above, the ownership interests of CET includes Gloria and Cumberland, while the remaining interest is owned by Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were $75,704, $71,182 and $59,255 for the years ended December 31, 2018, 2017 and 2016, respectively. Effective January 1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC"). CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.

Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.

Segment Reporting

The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States. Total revenues are primarily attributable to U.S. customers. Net revenues from customers outside the United States were approximately $2.1 million, $1.6 million and $2.0 million for the years ended December 31, 2018, 2017 and 2016, respectively.

Fair Value of Financial Instruments

Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:

Level 1 - Quoted prices for identical instruments in active markets.

Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 - Significant inputs to the valuation model are unobservable.

We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.

The Company’s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.

The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment. The Company has no marketable securities in which the fair value is determined based on Level 3. The level of management judgment required in evaluating fair value for Level 1 investments is minimal. Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The

Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).

The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model. Consist with Level 3 fair value measurements there are significant inputs to the valuation model that are unobservable.

Cash and Cash Equivalents

Cash and cash equivalents include highly liquid investments with original maturities of three months or less. As of December 31, 2018 and 2017, cash equivalents consist primarily of money market funds.

Marketable Securities

The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (“SBA”) loan pools, and corporate bonds. At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time. As of December 31, 2018 and 2017, marketable securities were comprised solely of trading securities. Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.

Accounts Receivable

Trade accounts receivable are recorded at the invoiced amount. The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks, cash discounts and credits for damaged product. The Company reviews each customer balance to assess collection status.

The majority of the Company’s products are distributed through independent pharmaceutical wholesalers. The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.

Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed.

Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.

Inventories

The Company works closely with third parties to manufacture and package finished goods for sale. Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale. As discussed below, effective January 1, 2017, inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.

The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value. The Company classifies the Vibativ inventories that it does not expect to sell within one year as non-current inventories.

Prepaid and Other Current Assets

Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA"). The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.

Deferred offering costs are expenses directly related to the Form S-3 or Shelf Registration filed with the SEC on November 11, 2017 and declared effective on January 16, 2018. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration, with any remaining deferred offering costs to be charged to the results of operations at the end of the three-year life of the Shelf Registration. During the year ended December 31, 2018, the Company has not expensed any deferred offering costs associated with the Shelf Registration.

Property and Equipment

Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations. Improvements that extend an asset’s useful life are capitalized. Repairs and maintenance costs are expensed as incurred.

Intangible Assets and Goodwill

The Company’s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes.

The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use. These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors. This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate. If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.

Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.

Amortization expense is recognized ratably over the following periods:


Product rights						Estimated economic life
License rights						Term of license agreement
Patents						Life of patent

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.

Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment. The Company's goodwill was acquired in November 2018 with the Vibativ acquisition. The Company recorded no impairment charges during 2018, 2017 and 2016.

Revenue Recognition

Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board’s (“FASB”) amended guidance in the form of Accounting Standards Update (“ASU”) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.

Net Product Revenue

Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company’s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments.

Sales Rebates and Discounts

The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.

Sales Returns

Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company’s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.

Other Revenues

Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services. Revenue related to grants is recognized when all conditions related to such grants have been met. All other revenue is recognized when earned.

Cost of Products Sold

Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.

Selling and Marketing Expense

Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.

Distribution Costs

Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:


	2018		2017		2016

Distribution costs	$	618,756	$	621,142	$	703,353

Advertising Costs

Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:


	2018		2017		2016

Advertising costs	$	2,219,074	$	2,589,185	$	2,626,238

Research and Development

Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company’s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.

Income Taxes

The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company’s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is “more likely than not” that the position would be sustained upon examination by the taxing authorities.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment.

The Company’s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.

Comprehensive Income (Loss)

Total comprehensive income (loss) was comprised solely of net income (loss) for all periods presented.

Earnings (Loss) per Share

Basic earnings per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.

Share-Based Payments

The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.

Collaborative Agreements

The Company is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, Collaborative Agreements. The agreements do not specifically designate each party's rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration ("SBIR/STTR") grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses in the consolidated statements of operations. Funding received from private sector investments and grants are recorded as net revenues in the consolidated statements of operations.

Recent Accounting Guidance

Recent Adopted Accounting Pronouncements

In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard.

The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue.

In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.

In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.

Recent Accounting Pronouncements - Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.

In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-02, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense

recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients. In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the practical expedients. This will allow the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. The Company expects the primary effect of adopting ASU 2016-02 will be to record right-of-use assets and obligations for our leases currently classified as operating leases. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023. These operating leases are expected to result in initial ROU assets and liabilities as of January 1, 2019 of between $3.6 million and $4.2 million.

Omeclamox®-Pak, Ethyol®, RediTrex®, Totect® and Vibativ®

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Omeclamox®-Pak, Ethyol®, Totect® and Methotrexate®

Omeclamox^®-Pak, Ethyol^®, RediTrex^®, Totect^® and Vibativ^®

Omeclamox-Pak

In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak including the Product’s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $2.3 million during 2018 and ended Cumberland’s payments of royalties and manufacturing fees to GEL. The Company has now assumed responsibility for the maintenance of the Product’s FDA approval and for the oversight of the Product’s manufacturing and packaging.

This agreement follows the November 2015 agreement between Cumberland and GEL to assume the remaining commercial rights to Omeclamox-Pak for the United States. The Company had previously signed an agreement with Pernix Therapeutics ("Pernix") to jointly commercialize the product in the United States in October 2013. As part of the November 2015 GEL Agreement, Cumberland and Pernix terminated their arrangements.

The $4.0 million upfront payment that the Company paid in October 2013 to Pernix along with the payments made to GEL during 2018 are included in product and license rights and are being amortized over the remaining expected useful life of the acquired asset. The Company evaluated the remaining expected useful life and maintained the existing estimated life of the product, June 2032. Omeclamox-Pak contributed $0.6 million, $1.8 million, and $2.5 million in net revenues during 2018, 2017, and 2016, respectively.

Ethyol

During May 2016, the Company announced an agreement with Clinigen Group Plc ("Clinigen") in which Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Ethyol is a FDA approved cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.

Under the terms of the agreement, Cumberland is responsible for all marketing, promotion, and distribution of the product in the United States. There were no upfront payments required under the agreement. Royalty payments ranging from 30% to 50% based on tiered levels of net sales are paid by Cumberland to Clinigen. The Company began generating revenue from the sale of Ethyol during the third quarter of 2016. Ethyol contributed $10.5 million, $10.8 million and $0.8 million in net revenues during 2018, 2017 and 2016, respectively.

RediTrex

In November 2016, the Company announced an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.’s ("Nordic") injectable methotrexate product line. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. The product line is approved for patient use in various European countries and Cumberland is in the process of registering and commercialize the products in the United States.

Under the terms of the Agreement, Cumberland is responsible for the products’ FDA submission and registration. The regulatory submission are based on the dossier provided by Nordic. As consideration for the license, Cumberland paid a deposit of $100,000 and recorded an initial liability of $900,000 provided through 180,000 unvested restricted shares of Cumberland stock, valued on November 15, 2016, that will fully vest upon the FDA approval of the first Nordic product. Cumberland will also provide Nordic a series of payments tied to the products’ FDA approval, launch and achievement of certain sales milestones. Nordic will be responsible for manufacturing and supply of the products. The 180,000 shares of unvested restricted Cumberland stock was reflected in other current liabilities in the consolidated balance sheet and were valued at $1.1 million and $1.3 million at December 31, 2018 and 2017, respectively.

Totect

During January 2017, the Company announced an agreement with Clinigen in which Cumberland acquired the exclusive rights to commercialize Totect in the United States. Totect is an FDA-approved hospital based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy. It treats anthracycline extravasation that occurs when the injected medication escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications.

The Company launched Totect during a national shortage of dexrazoxane, resulting in strong initial demand for the product. It's our second oncology support product and the second product licensed to us through our Strategic Alliance with Clinigen.

Under the terms of the agreement, Cumberland is responsible for all marketing, promotion, and distribution of the product in the United States. There are no upfront payments required under the agreement. Royalty payments ranging from 30% to 50% based on tiered levels of net sales are paid by Cumberland to Clinigen. The Company began generating revenue from the sale of Totect during the third quarter of 2017. Totect contributed approximately $0.9 million and $4.0 million in net revenue during 2018. and 2017, respectively.

Vibativ

During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand. Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results. Cumberland is evaluating the tax deductibility of the goodwill acquired in the acquisition.

Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $20.0 million with a $5.0 million cash payment due in early 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product. The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination.

The following table summarizes the initial payments and consideration for the business combination:



Consideration:
Cash paid at closing	$	20,000,000
Cash payment during early 2019	5,000,000
Fair value of contingent consideration - net sales royalty	9,034,000
Total consideration	$	34,034,000

The contingent consideration liability represents the future net sales royalty payments discussed above. Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs. As a result, the valuations are classified as Level 3 fair value measurements. The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. Vibativ contributed $5.1 million in net revenues during 2018. The pro-forma effects of the acquisition on the consolidated financial statements were not deemed meaningful for disclosure purposes.

The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis. The current and long-term portions of this liability are disclosed in Note 8. The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.


	Contingent consideration liability
Balance at November 12, 2018	$	9,034,000
Change in fair value of contingent consideration included in operating expenses	(40,000)
Contingent consideration earned and accrued in operating expenses	508,000
Balance at December 31, 2018	$	9,502,000

The following table summarizes the preliminary allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:


Finished goods inventory	$	6,624,000
Work in process - unlabeled vials	3,970,000
Work in process - validation vials	1,827,000
Raw materials	9,129,000
Total inventory	$	21,550,000

Intellectual property amortizable intangible assets	$	11,700,000
Goodwill	784,000
Total intangibles and goodwill	$	12,484,000
Total assets acquired	$	34,034,000

Revenues

12 Months Ended

Dec. 31, 2018

Revenues [Abstract]

Revenues

Product Revenues

The Company’s net product revenues consisted of the following for the years ended December 31:


	2018		2017		2016
Products:
Acetadote	$	4,284,111	$	6,576,720	$	7,214,341
Omeclamox-Pak	623,297		1,761,868		2,536,027
Kristalose	12,055,625		11,455,805		15,898,760
Vaprisol	1,763,874		1,576,222		1,857,838
Caldolor	5,001,997		4,178,443		4,132,833
Ethyol	10,545,906		10,835,038		838,386
Totect	850,965		3,992,467		—
Vibativ	5,075,057		—		—
Total net product revenues	$	40,200,832	$	40,376,563	$	32,478,185

Cumberland supplies Perrigo Company ("Perrigo") with an Authorized Generic version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was $3.1 million, $4.6 million and $4.8 million during 2018, 2017 and 2016, respectively.

The allowances in accounts receivable for chargebacks, cash discounts and damaged goods were $0.9 million at December 31, 2018 and $0.5 million at December 31, 2017, and the accruals for rebates, product returns and certain administrative and service fees included in other current liabilities were $5.6 million and $4.7 million, at December 31, 2018 and 2017, respectively.

Other Revenues

The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable up-front payments at the time the agreements are entered into and payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company will recognize revenue for these achievements once it is probable that these consideration amounts are no longer constrained. The Company is also entitled to receive royalties on future sales of the products under the agreements. The international agreements provide for $1.5 million in non-refundable up-front payments, milestone payments of up to $2.4 million of milestone payments related to regulatory approvals and up to $4.6 million in payments related to product sales. As of December 31, 2018, the Company has recognized a cumulative $1.5 million in upfront payments as other revenue and has recognized $0.1 million in revenue related to the milestone payments associated with these international agreements.

Other revenues during 2018, 2017 and 2016 also includes revenue generated by CET through grant funding from federal Small Business grant programs, and lease income generated by CET’s Life Sciences Center and contract services. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from SBIR/STTR programs totaled approximately $0.1 million, $0.2 million, and $0.1 million for the years ending December 31, 2018, 2017 and 2016, respectively.

Inventories

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventories

The Company's net inventories consisted of the following as of December 31:


	2018		2017

Raw materials and work in process	$	18,378,450	$	3,156,002
Consigned inventory	937,006		249,964
Finished goods, net of reserve	8,511,887		3,331,882
Total inventories	27,827,343		6,737,848
less non-current inventories	(15,749,000)		—
Total inventories classified as current	$	12,078,343	$	6,737,848

The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value. At December 31, 2018 and 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.3 million and $0.2 million, respectively.

In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at December 31, 2018 and 2017. Consigned inventory represents Authorized Generic inventory stored with Perrigo until shipment. As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current and included in the raw materials and work in process inventory at December 31, 2018. Non-current inventories also include $0.8 million in Vibativ finished goods.

Property and Equipment

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consisted of the following at December 31:


	Range of useful lives	2018		2017

Computer equipment	3 – 5 years	$	1,148,140	$	1,074,172
Office equipment	3 – 15 years	809,153		457,945
Furniture and fixtures	5 – 15 years	639,267		633,577
Leasehold improvements	3 – 15 years, or remaining lease term	1,299,363		1,274,660
Total property and equipment, gross		3,895,923		3,440,354
Less: accumulated depreciation and amortization		(3,124,710)		(2,911,472)
Total property and equipment, net		$	771,213	$	528,882

Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations. Depreciation expense was as follows for the years ended December 31:


	2017		2016		2015

Depreciation expense	$	213,237	$	211,532	$	202,868

Intangible Assets

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible Assets and Goodwill

Intangible assets and Goodwill consisted of the following at December 31:


	2018		2017

Product and license rights	$	36,573,941	$	21,879,981
Less: accumulated amortization	(8,405,188)		(6,564,007)
Total product and license rights	28,168,753		15,315,974
Patents	9,428,266		9,177,647
Less: accumulated amortization	(4,087,273)		(3,158,990)
Total patents	5,340,993		6,018,657
Trademarks	154,373		118,934
Less: accumulated amortization	(9,020)		(9,020)
Total trademarks	145,353		109,914
Total intangible assets	$	33,655,099	$	21,444,545

Goodwill	$	784,000	$	—

During 2013, the Company entered into an agreement with Pernix to distribute and promote the branded prescription product Omeclamox-Pak. The $4.0 million upfront payment the Company paid to Pernix during October 2013 and the $2.3 million payments made to GEL during 2018 (discussed more fully in Note 3) are included in product and license rights and are being amortized through June 2032, the remaining expected useful life of the acquired asset.

During 2014, the Company acquired the rights of the branded prescription product Vaprisol from Astellas. The intangible asset value is $3.0 million and is included in product and license rights. The asset is being amortized through February 2022, the remaining expected useful life of the acquired asset, which coincides with the life of the primary intellectual property asset.

In November 2016, the Company acquired the U.S. rights to Nordic Group B.V.’s injectable methotrexate product line. The agreement requires the Company to make future milestone payments over a fifteen-year period from the effective grant of the Regulatory Approval of the Methotrexate Pre-Filled Syringe Product in the U.S. The payments are being treated as consideration for the assets acquired and are being capitalized and will be amortized over the expected useful life of the acquired asset, once approval is granted. During 2017, the Company paid a deposit of $100,000 as well as recorded a liability provided through 180,000 unvested restricted shares of Cumberland stock, that will fully vest upon the FDA approval of the first Nordic product. As of December 31, 2018, the 180,000 shares of unvested restricted Cumberland stock are valued at $1.1 million.

As discussed in Note 3, during November 2018, the Company acquired Vibativ from Theravance. This resulted in amortizable intangible assets related to the product rights of $11.7 million and goodwill of $0.8 million. The intangible assets are being amortized through November 2028, the expected useful life of the acquired asset.

During 2018 and 2017, the Company recorded an additional $0.4 million and $0.4 million, respectively, in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property. These costs will be amortized over the remaining expected useful life of the associated patents.

Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:


	2018		2017		2016

Amortization expense	$	2,769,466	$	2,436,222	$	2,194,039

The expected amortization expense for the Company's current balance of intangible assets are as follows:


Year ending December 31:
2019	$	3,658,612
2020	3,737,638
2021	3,737,638
2022	3,426,180
2023 and thereafter	19,095,031
	$	33,655,099

Debt	12 Months Ended
Debt	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt	Debt On October 17, 2018, the Company entered into a second amendment (“Second Amendment”) to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (“Pinnacle Agreement”). The Second Amendment increases the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million. Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes. The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions. The Second Amendment does not affect the term of the Pinnacle Agreement, which has a three year term expiring on July 31, 2020. The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had $20.0 million in borrowings under the Pinnacle Agreement at December 31, 2018 and $9.8 million at December 31, 2017. As of December 31, 2018, the Company had used all of its available borrowing under its revolving line of credit. The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 4.3% at December 31, 2018). In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. Borrowings under the line of credit are collateralized by substantially all of our assets. Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis. On August 14, 2018 the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment. The Company achieved compliance with the financial covenant as of December 31, 2018 through the utilization of the covenant cure section of the Pinnacle Agreement.

Shareholders' Equity	12 Months Ended
Shareholders' Equity	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity (a) Initial Public Offering On August 10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. Contemporaneously with the offering, each outstanding share of preferred stock was automatically converted into two million shares of common stock. (b) Preferred Stock The Company is authorized to issue 20,000,000 shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December 31, 2018 and 2017, there was no preferred stock outstanding. (c) Common Stock During 2018, 2017 and 2016, the Company issued 170,759 shares, 146,275 shares, and 223,987 shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances. Cumberland issued 3,409 common shares under option exercise transactions during 2016. There were no option exercise transactions during 2018 and 2017. The payment of dividends is restricted by the Agreement with the Company’s primary lender. In January 2018, the Company's Form S-3 or Shelf Registration associated with the sale of up to $100 million in corporate securities was declared effective. The Shelf Registration also included an At the Market ("ATM") feature enabling the Company to sell common shares at market prices, along with an agreement with B. Riley FBR to support such a placement of shares. (d) Warrants In 2006, the Company signed a new line of credit agreement along with a term loan agreement with a financial institution. In conjunction with these agreements, the Company issued warrants to purchase up to 3,958 shares of common stock at $9.00 per share within 10 years of issuance. All of these warrants expired during 2017. In connection with the amendment to the debt agreements in 2009, the Company issued warrants to purchase up to 7,500 shares of common stock at $17.00 per share that expire in July 2019. All of these warrants were outstanding and exercisable as of December 31, 2018 and 2017. (e) Share Repurchases The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Act. In January 2016 and again during January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. The Company repurchased 443,041 shares, 547,376 shares and 529,312 shares of common stock for approximately $2.9 million, $3.7 million, and $2.5 million during the years ended December 31, 2018, 2017 and 2016, respectively. (f) Cumberland Emerging Technologies In April 2014, the Company received approximately $1 million from Gloria for its participation in CET. As a result, Gloria received shares in CET and will have the first right to negotiate a license to CET developed products for the Chinese market. Prior to April 2014, Cumberland owned 85% of CET, with the balance of the enterprise being owned by Vanderbilt University and the Tennessee Technology Development Corporation. In connection with Gloria’s investment in CET, the Company also provided an additional investment in CET. Cumberland contributed $1.0 million in cash and provided $2.4 million in loan forgiveness to CET in exchange for newly issued shares. Upon completion of the additional investment by Gloria and Cumberland in April 2014, the Company’s ownership in CET is 80%. As CET is a consolidated subsidiary, the Company reports the operating results of CET and allocates the noncontrolling interests to the non-majority partners. (g) Cumberland Foundation In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation’s Board of Directors was initially comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation’s ongoing activities including charitable contributions. Cumberland provided a grant of 50,000 shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the organization, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation’s future. The Foundation will maintain separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation are expected to equal approximately 5% of the Foundation’s total holdings, which is consistent with the historic level of contributions made by Cumberland Pharmaceuticals.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

The components of the Company's net deferred tax assets at December 31 are as follows:


	2018		2017

Deferred Tax Assets
Net operating loss and tax credits	$	16,410,403	$	15,295,547
Property and equipment and intangibles	236,318		232,667
Allowance for accounts receivable	251,068		129,180
Reserve for expired product	558,484		538,141
Inventory	193,150		173,885
Deferred charges	910,577		624,367
Cumulative compensation costs incurred on deductible equity awards	884,049		793,206
Total deferred tax assets	19,444,049		17,786,993

Deferred Tax Liabilities
Intangible assets	(1,974,787)		(2,067,548)
Net deferred tax assets, before valuation allowance	17,469,262		15,719,445
Less: deferred tax asset valuation allowance	(17,382,052)		(15,632,235)
Net deferred tax assets	$	87,210	$	87,210

The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December 31, 2018:


Years of expiration	Federal		State

2019	$	—	$	238,047
2020 - 2028	—		38,886,662
2029	44,153,819		10,508,184
2030 - 2037	7,534,351		9,617,093
Indefinite Period	3,918,317		137,040

Total federal and state net operating loss carryforwards	$	55,606,487	$	59,387,026

Income tax (expense) benefit includes the following components for the years ended December 31:


	2018		2017		2016

Current:
Federal	$	—	$	—	$	867,041
State and other	(16,636)		(59,243)		83,463
Total current income tax (expense) benefit	(16,636)		(59,243)		950,504

Deferred:
Federal	—		(3,682,772)		(537,965)
State	—		(432,874)		(81,615)
Total deferred income tax (expense) benefit	—		(4,115,646)		(619,580)
Total income tax (expense) benefit	$	(16,636)	$	(4,174,889)	$	330,924

The Company’s effective income tax rate for 2018, 2017 and 2016 reconciles with the federal statutory tax rate as follows:


	2018		2017		2016

Federal tax expense at statutory rate	21	%	34	%	34	%
State income tax expense (net of federal income tax benefit)	4	%	4	%	4	%
Permanent differences associated with general business credits	1	%	1	%	5	%
Change in valuation allowance	(25)	%	(148)	%	(15)	%
Change in tax rate	—	%	2	%	—	%
Other permanent differences	(1)	%	1	%	(2)	%
Other	—	%	(2)	%	(1)	%
Net income tax expense	—	%	(108)	%	25	%

In 2017, the Company determined that it was not more likely than not that its net deferred tax assets would be realized. As such, the Company’s income tax provision for the year ended December 31, 2017 reflected a full valuation allowance against net deferred tax assets with the exception of the deferred tax asset for alternative minimum tax (“AMT”) credit carryforwards discussed further below. The Company’s position is unchanged as of December 31, 2018.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (“the Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (“AMT”) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.

In connection with our analysis of the impact of the Tax Act, we recorded a net tax benefit of $0.1 million in the period ended December 31, 2017. This net tax benefit consisted entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. While the Company does not expect to record further amounts related to the Tax Act, we will continue to evaluate additional guidance as it is released by the Internal Revenue Service and will record additional amounts if needed.

The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.

Federal tax years that remain open to examination are 2012 through 2017. Due to a 2009 net operating loss carryback, federal tax years 2006 through 2008 remain open to the extent of net operating losses utilized in those years. During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments. State tax years that remain open to examination are 2011 to 2017. The Company has no unrecognized tax benefits in 2018, 2017 and 2016.

Stock-Based Compensation Plans

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation Plans

The Company has grants outstanding under three equity compensation plans, with two of the plans available for future grants of equity compensation awards to employees, consultants and directors. All of the equity plans were approved by shareholders. The 2007 Long-Term Incentive Compensation Plan (the 2007 Plan) and the 2007 Directors’ Incentive Plan (the "Directors’ Plan") superseded the 1999 Stock Option Plan. The 2007 Plan and the Directors’ Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 2.4 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors’ Plan.

The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is ten years from the date of grant, except for incentive stock options granted to 10% shareholders, which is five years.

During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the one year anniversary of the date of grant.

Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense consisted of the following for the years ended December 31:


	2018		2017		2016

Share-based compensation - employees	$	1,244,606	$	1,032,094	$	833,027
Share-based compensation - nonemployees	120,092		82,969		19,075
Share-based compensation - foundation contribution	$	—	$	372,500	$	—
Total share-based compensation	$	1,364,698	$	1,487,563	$	852,102

At December 31, 2018, there was approximately $2.4 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 2.6 years. This amount relates primarily to unrecognized compensation cost for employee restricted stock awards.

Stock Options

Stock option activity for 2018 and 2017 was as follows:


	Number of shares	Weighted-average exercise price per share		Weighted- average remaining contractual term (years)	Aggregate intrinsic value

Outstanding, December 31, 2016	5,800	$	13.00	1.9	$	—
Options granted	—	—
Options exercised	—	—
Options forfeited or expired	—	—
Outstanding, December 31, 2017	5,800	13.00		0.9	—
Options granted	—	—
Options exercised	—	—
Options forfeited or expired	—	—
Outstanding, December 31, 2018	5,800	13.00		0.1	—
Exercisable at December 31, 2018	5,800	$	13.00	0.1	$	—

The Company did not grant any stock options during 2018, 2017 and 2016, and no options were exercised during 2018 and 2017. Information related to the stock option plans during 2018, 2017 and 2016 was as follows:


	2018		2017		2016

Intrinsic value of options exercised	$	—	$	—	$	—
Weighted-average fair value of options exercised	$	—	$	—	$	—

Restricted Stock Awards

Restricted stock activity was as follows:


	Number of shares	Weighted- average grant-date fair value

Nonvested, December 31, 2016	703,295	$	5.13
Shares granted	238,550	6.48
Shares vested	(146,275)	4.74
Shares forfeited	(27,725)	5.34
Nonvested, December 31, 2017	767,845	5.61
Shares granted	261,680	6.66
Shares vested	(170,759)	4.79
Shares forfeited	(25,025)	6.19
Nonvested, December 31, 2018	833,741	$	6.09

The fair value of restricted stock granted was based on the closing market price of the Company’s common stock on the date of grant. The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest. Once vested they are included in the basic weighted shares outstanding computation.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2018
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans The Company sponsors an employee benefit plan that was established on January 1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the Plan), under Section 401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2018, 2017 and 2016, the Company contributed approximately $50,000 in each year to the Plan as an employer match of participant contributions. In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheet, was $1.6 million and as of December 31, 2018 and 2017. The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $2.3 million as of December 31, 2018 and 2017, respectively.

Leases

12 Months Ended

Dec. 31, 2018

Leases [Abstract]

Leases

The Company is obligated under long-term real estate leases for corporate office space that was extended during the third quarter of 2015. Prior to this extension, the lease would have expired in October 2016, the lease is now set to expire in October 2022. In addition, the research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases.

Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis. Rent expense and sublease income were as follows for the years ended December 31:


	2018		2017		2016

Rent expense	$	1,136,610	$	1,074,437	$	1,150,614

Sublease income	$	662,358	$	573,494	$	646,235

Cumulative future minimum sublease income under noncancelable operating subleases totals approximately $0.3 million and will be paid through the leases ending in February 2019, March 2019, and October 2022. Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:


Year ending December 31:
2019	$	959,902
2020	980,720
2021	1,001,603
2022	871,969
2023	44,508
2024 and thereafter	—
Total future minimum lease payments	$	3,858,702

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

The Company owns marketable securities that are solely classified as trading securities as of December 31, 2018. There were no transfers of assets between levels within the fair value hierarchy. The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:


	December 31, 2018										December 31, 2017
	Level 1		Level 2		Total		Level 1		Level 2		Total

U.S. Treasury notes and bonds	$	5,034,955	$	—	$	5,034,955	$	—	$	—	$	—
U.S. Agency issued mortgage-backed securities - variable rate	—		—		—		—		3,539,102		3,539,102
U.S. Agency notes and bonds - fixed rate	—		—		—		—		198,293		198,293
Corporate bonds	—		2,504,551		2,504,551
SBA loan pools - variable rate	—		—		—		—		935,081		935,081
Short-term cash investments	—		751,173		751,173		—		—		—
Total fair value of marketable securities	$	5,034,955	$	3,255,724	$	8,290,679	$	—	$	4,672,476	$	4,672,476

The fair values of all other financial instruments outstanding as of December 31, 2018 and 2017 approximate their carrying values. There were no changes to the valuation techniques for the Level 2 marketable securities during 2018 or 2017.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Market Concentrations

12 Months Ended

Dec. 31, 2018

Risks and Uncertainties [Abstract]

Market Concentrations

The Company currently focuses on the acquisition, development and commercialization of branded prescription products for the hospital acute care, gastroenterology, and oncology supportive care markets. The Company’s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company’s cash equivalents consist primarily of money market funds. Certain bank deposits may at times be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.

The Company’s primary customers are wholesale pharmaceutical distributors in the U.S. Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:


	2018	2017	2016

Customer 1	26%	25%	22%
Customer 2	24%	22%	28%
Customer 3	25%	25%	29%
Customer 4	*%	*%	10%
Customer 5	11%	*%	*%
*: less than 10% of total

The Company’s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 78% and 53% at December 31, 2018 and 2017, respectively.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments In connection with the acquisition of certain Kristalose assets during 2011, the Company was required to make quarterly payments based on a percentage of Kristalose net sales through November 2018. The payments are being treated as consideration for the assets acquired, and are being capitalized and amortized over the remaining expected useful life of the acquired asset, currently through 2026. In connection with its licensing agreements for Caldolor, Ethyol, and Totect, the Company is required to pay royalties based on net sales over the life of the contracts. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product. At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. Legal Matters In April 2012, the United States Patent and Trademark Office (the “USPTO”) issued U.S. Patent number 8,148,356 (the “356 Acetadote Patent”) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO. Following the issuance of the 356 Acetadote Patent, the Company received separate Paragraph IV certification notices from InnoPharma, Inc. ("InnoPharma"), Paddock Laboratories, LLC (“Paddock”), Mylan Institutional LLC (“Mylan”), Sagent Agila LLC ("Sagent") and Perrigo Company ("Perrigo") challenging the 356 Acetadote Patent on the basis of non-infringement and/or invalidity. The Company responded by filing five separate infringement lawsuits, in the appropriate United States District Courts, to contest each of the challenges. On November 12, 2012, the Company entered into a Settlement Agreement (the “Settlement Agreement”) with Paddock and Perrigo to resolve the challenges and the pending litigation with those two companies. On November 1, 2013, the United States District Court filed opinions granting Sagent’s and InnoPharma’s motions to dismiss the Company's suits and the Company agreed not to file an appeal or motion to reconsider, thereby resolving the challenges and the pending litigation with those two companies. Under the Settlement Agreement, Paddock and Perrigo admit that the 356 Acetadote Patent is valid and enforceable and that any Paddock or Perrigo generic version of Acetadote (with or without EDTA) would infringe upon the 356 Acetadote Patent. In addition, Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the 356 Acetadote Patent through its expiration currently scheduled for May 2026. On November 12, 2012, in connection with the execution of the Settlement Agreement, Cumberland entered into a License and Supply Agreement with Paddock and Perrigo (the “License and Supply Agreement”). Under the terms of the License and Supply Agreement, if a third party receives final approval from the FDA for an ANDA to sell a generic Acetadote product and such third party has made such generic version available for purchase in commercial quantities in the United States, the Company supply's Perrigo with an Authorized Generic version of its Acetadote product. On May 18, 2012, Cumberland also submitted a Citizen Petition to the FDA requesting that the FDA refrain from approving any applications for acetylcysteine injection that contain EDTA, based in part on the FDA's request that the Company evaluate the reduction or removal of EDTA from its original Acetadote formulation. On November 7, 2012, the FDA responded to the Citizen Petition denying its request and stating that ANDAs referencing Acetadote that contain EDTA may be accepted and approved provided they meet all applicable requirements. The Company believes this response contradicts the FDA's request to evaluate the reduction or removal of EDTA. On November 8, 2012, the Company learned that the FDA approved the ANDA referencing Acetadote filed by InnoPharma, Inc. On November 3, 2012, Cumberland brought suit against the FDA in the United States District Court for the District of Columbia alleging that the FDA's denial of our Citizen Petition and acceptance for review and approval of any InnoPharma, Inc. product containing EDTA was arbitrary and in violation of law. The Company found during the resulting legal proceedings that the FDA initially concluded that the original Acetadote formulation was withdrawn for safety reasons and no generic versions should be approved. The FDA later reversed its position based on the possibility of drug shortages and the presence of EDTA in other formulations. At the same time, the FDA noted that exclusively marketing a non-EDTA containing product would be preferable because it would eliminate the potential risk of EDTA. On January 7, 2013, Perrigo announced initial distribution of Cumberland's Authorized Generic acetylcysteine injection product. On March 19, 2013, the USPTO issued U.S. Patent number 8,399,445 (the “445 Acetadote Patent”) which is also assigned to Cumberland. The claims of the 445 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose. On April 8, 2013, the 445 Acetadote Patent was listed in the FDA Orange Book. The 445 Acetadote Patent is scheduled to expire in August 2025. Following the issuance of the 445 Acetadote Patent Cumberland received separate Paragraph IV certification notices from Perrigo, Sagent, and Mylan Institutional LLC challenging the 445 Acetadote Patent on the basis of non-infringement, unenforceability and/or invalidity. On June 10, 2013, The Company became aware of a Paragraph IV certification notice from Akorn, Inc. challenging the 445 Acetadote Patent and the 356 Acetadote Patent on the basis of non-infringement. On July 12, 2013, Cumberland filed a lawsuit for infringement of the 356 Acetadote Patent against Akorn, Inc. in the United States District Court for the District of Delaware. On June 10, 2013, the Company announced that the FDA approved updated labeling for Acetadote. The new labeling revises the product's indication and offers new dosing guidance for specific patient populations. On September 30, 2013, the United States District Court for the District of Columbia filed an opinion granting a Summary Judgment in favor of the FDA regarding Cumberland’s November 13, 2012 suit. On November 1, 2013, the United States District Court for the District of Delaware filed opinions granting Sagent’s and InnoPharma’s motions to dismiss its May 2012 and June 2012 suits. On February18, 2014, the USPTO issued U.S. Patent number 8,653,061 (the “061 Acetadote Patent”) which is assigned to the Company. The claims of the 061 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose. Following its issuance, the 061 Acetadote Patent was listed in the FDA Orange Book. The 061 Acetadote Patent is scheduled to expire in August 2025. On May 13, 2014, the USPTO issued U.S. Patent number 8,722,738 (the “738 Acetadote Patent”) which is assigned to Cumberland. The claims of the 738 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 738 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in April 2032. On December 11, 2014 and March 3, 2015, the Company became aware of Paragraph IV certification notices from Aurobindo Pharma Limited and Zydus Pharmaceuticals (USA) Inc., respectively, challenging the 356, 445, 061, and 738 Acetadote Patents on the basis of non-infringement. By statute, where the Paragraph IV certification is to a patent timely listed before an Abbreviated New Drug Application (“ANDA”) is filed, a company has 45 days to institute a patent infringement lawsuit during which period the FDA may not approve another application. In addition, such a lawsuit for patent infringement filed within such 45-day period may stay, or bar, the FDA from approving another product application for two and a half years or until a district court decision that is adverse to the asserted patents, whichever is earlier. On February 10, 2015, the USPTO issued U.S. Patent number 8,952,065 (the “065 Acetadote Patent”) which is assigned to us. The claims of the 065 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acute liver failure. The 065 Acetadote Patent is scheduled to expire in August 2025. On September 30, 2015, the United States District Court for the Northern District of Illinois, Eastern Division ("District Court") ruled in our favor in our lawsuit against Mylan for infringement of the 445 Acetadote Patent. The opinion upheld our 445 Acetadote Patent and expressly rejected Mylan's validity challenge. The District Court ruled that Mylan is liable to us for infringement of the 445 Acetadote patent in light of Mylan's Abbreviated New Drug Application in which Mylan sought to market a generic version of Acetadote. On November 17, 2015, the District Court entered an order enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until August 2025, the date of expiration of the 445 Acetadote Patent. On October 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the "Appeals Court"). On May 3, 2016, the USPTO issued U.S. Patent number 9,327,028 (the “028 Acetadote Patent”) which is assigned to us. The claims of the 028 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 028 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in July 2031. On January 26, 2017, the Appeals Court affirmed the District Court ruling in the Company's favor in its lawsuit against Mylan for infringement of the 445 Acetadote Patent. The Appeals Court opinion affirmed the District Court’s ruling upholding Cumberland's 445 Acetadote Patent and expressly rejected Mylan's validity challenge. On November 3, 2017, the Company became aware of a Paragraph IV certification notice from Exela Pharma Sciences, LLC challenging the 356, 445, 061, 738, and 028 Acetadote Patents on the basis of non-infringement. The Company continues to consider its legal options and intends to continue to vigorously defend and protect its Acetadote product and related intellectual property rights. The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, other than the issue concerning the Company's Acetadote patents discussed above, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.

Quarterly Financial Information (Unaudited)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information (Unaudited)

The following table sets forth the unaudited operating results for each fiscal quarter of 2018 and 2017:


	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total

2018:
Net revenues	$	8,587,605	$	10,163,724	$	8,492,530	$	13,497,906	$	40,741,765
Operating income (loss)	(2,452,222)		(868,978)		(1,806,883)		(2,262,689)		(7,390,772)
Net income (loss) attributable to common shareholders	(2,379,239)		(720,688)		(1,643,044)		(2,220,097)		(6,963,068)
Earnings (loss) per share attributable to common shareholders ⁽¹⁾
Basic	$	(0.15)	$	(0.05)	$	(0.11)	$	(0.14)	$	(0.45)
Diluted	$	(0.15)	$	(0.05)	$	(0.11)	$	(0.14)	$	(0.45)

2017:
Net revenues	$	9,636,755	$	8,667,127	$	11,196,961	$	11,649,288	$	41,150,131
Operating income (loss)	(657,802)		(1,680,871)		(839,349)		(903,326)		(4,081,348)
Net income (loss) attributable to common shareholders	(1,274,446)		(5,160,611)		(743,031)		(800,545)		(7,978,633)
Earnings (loss) per share attributable to common shareholders ⁽¹⁾
Basic	$	(0.08)	$	(0.32)	$	(0.05)	$	(0.05)	$	(0.50)
Diluted	$	(0.08)	$	(0.32)	$	(0.05)	$	(0.05)	$	(0.50)

(1) Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.
Use of Estimates	Use of EstimatesThe preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions.
Segment Reporting	Segment ReportingThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States. Total revenues are primarily attributable to U.S. customers.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below: Level 1 - Quoted prices for identical instruments in active markets. Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 - Significant inputs to the valuation model are unobservable. We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis. The Company’s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate. The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such services' pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment. The Company has no marketable securities in which the fair value is determined based on Level 3. The level of management judgment required in evaluating fair value for Level 1 investments is minimal. Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. The Company believes that the valuations provided by the third-party pricing service, as derived from such services' pricing models, represent prices that would be received to sell the assets at the measurement date (exit prices).The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model. Consist with Level 3 fair value measurements there are significant inputs to the valuation model that are unobservable.
Cash and Cash Equivalents	Cash and Cash EquivalentsCash and cash equivalents include highly liquid investments with original maturities of three months or less. As of December 31, 2018 and 2017, cash equivalents consist primarily of money market funds.
Marketable Securities	Marketable Securities The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (“SBA”) loan pools, and corporate bonds. At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time. As of December 31, 2018 and 2017, marketable securities were comprised solely of trading securities. Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded at the invoiced amount. The Company records allowances for amounts that could become uncollectible in the future based on historical experience, including amounts related to chargebacks, cash discounts and credits for damaged product. The Company reviews each customer balance to assess collection status. The majority of the Company’s products are distributed through independent pharmaceutical wholesalers. The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product. Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.
Inventories	Inventories The Company works closely with third parties to manufacture and package finished goods for sale. Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale. As discussed below, effective January 1, 2017, inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value. The Company classifies the Vibativ inventories that it does not expect to sell within one year as non-current inventories.
Prepaid and Other Current Assets	Prepaid and Other Current Assets Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA"). The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.
Property and Equipment	Property and Equipment Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations. Improvements that extend an asset’s useful life are capitalized. Repairs and maintenance costs are expensed as incurred.
Intangible Assets	Intangible Assets and Goodwill The Company’s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ acquisition. Goodwill is not amortized for financial reporting purposes. The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use. These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors. This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate. If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life. Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred. Amortization expense is recognized ratably over the following periods:
Impairment of Long-Lived Assets	Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board’s (“FASB”) amended guidance in the form of Accounting Standards Update (“ASU”) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. Net Product Revenue Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company’s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. Sales Rebates and Discounts The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product. Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed. Sales Returns Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company’s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed. Other Revenues Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services. Revenue related to grants is recognized when all conditions related to such grants have been met. All other revenue is recognized when earned.
Cost of Products Sold	Cost of Products Sold Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.
Selling and Marketing Expense	Selling and Marketing Expense Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.
Distribution Costs	Distribution CostsDistribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.
Advertising Costs	Advertising CostsAdvertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.
Research and Development	Research and Development Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company’s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.
Income Taxes	Income Taxes The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company’s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is “more likely than not” that the position would be sustained upon examination by the taxing authorities. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. The Company’s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Total comprehensive income (loss) was comprised solely of net income (loss) for all periods presented.
Earnings (Loss) Per Share	Earnings (Loss) per Share Basic earnings per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.
Share-Based Payments	Share-Based Payments The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.
Collaborative Agreements	Collaborative Agreements The Company is a party to several collaborative arrangements with certain research institutions to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company has determined these collaborative agreements do not meet the criteria for accounting under Accounting Standards Codification 808, Collaborative Agreements. The agreements do not specifically designate each party's rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is generally provided through private sector investments or federal Small Business Administration ("SBIR/STTR") grant programs. Expenses incurred under these collaborative agreements are included in research and development expenses in the consolidated statements of operations. Funding received from private sector investments and grants are recorded as net revenues in the consolidated statements of operations.
Recent Accounting Guidance	Recent Accounting Guidance Recent Adopted Accounting Pronouncements In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows. In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows. Recent Accounting Pronouncements - Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables. In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-02, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients. In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the practical expedients. This will allow the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. The Company expects the primary effect of adopting ASU 2016-02 will be to record right-of-use assets and obligations for our leases currently classified as operating leases. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023. These operating leases are expected to result in initial ROU assets and liabilities as of January 1, 2019 of between $3.6 million and $4.2 million.

Omeclamox®-Pak, Ethyol®, RediTrex®, Totect® and Vibativ® (Tables)

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The following table summarizes the initial payments and consideration for the business combination:



Consideration:
Cash paid at closing	$	20,000,000
Cash payment during early 2019	5,000,000
Fair value of contingent consideration - net sales royalty	9,034,000
Total consideration	$	34,034,000

Schedule of Business Acquisitions by Acquisition, Contingent Consideration


	Contingent consideration liability
Balance at November 12, 2018	$	9,034,000
Change in fair value of contingent consideration included in operating expenses	(40,000)
Contingent consideration earned and accrued in operating expenses	508,000
Balance at December 31, 2018	$	9,502,000

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary allocation of the fair values of the assets acquired as of the acquisition date for Vibativ:


Finished goods inventory	$	6,624,000
Work in process - unlabeled vials	3,970,000
Work in process - validation vials	1,827,000
Raw materials	9,129,000
Total inventory	$	21,550,000

Intellectual property amortizable intangible assets	$	11,700,000
Goodwill	784,000
Total intangibles and goodwill	$	12,484,000
Total assets acquired	$	34,034,000

Inventories (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Schedule of inventories, current

The Company's net inventories consisted of the following as of December 31:


	2018		2017

Raw materials and work in process	$	18,378,450	$	3,156,002
Consigned inventory	937,006		249,964
Finished goods, net of reserve	8,511,887		3,331,882
Total inventories	27,827,343		6,737,848
less non-current inventories	(15,749,000)		—
Total inventories classified as current	$	12,078,343	$	6,737,848

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

Property and equipment consisted of the following at December 31:


	Range of useful lives	2018		2017

Computer equipment	3 – 5 years	$	1,148,140	$	1,074,172
Office equipment	3 – 15 years	809,153		457,945
Furniture and fixtures	5 – 15 years	639,267		633,577
Leasehold improvements	3 – 15 years, or remaining lease term	1,299,363		1,274,660
Total property and equipment, gross		3,895,923		3,440,354
Less: accumulated depreciation and amortization		(3,124,710)		(2,911,472)
Total property and equipment, net		$	771,213	$	528,882

Schedule of depreciation expense

Depreciation expense was as follows for the years ended December 31:


	2017		2016		2015

Depreciation expense	$	213,237	$	211,532	$	202,868

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

Intangible assets and Goodwill consisted of the following at December 31:


	2018		2017

Product and license rights	$	36,573,941	$	21,879,981
Less: accumulated amortization	(8,405,188)		(6,564,007)
Total product and license rights	28,168,753		15,315,974
Patents	9,428,266		9,177,647
Less: accumulated amortization	(4,087,273)		(3,158,990)
Total patents	5,340,993		6,018,657
Trademarks	154,373		118,934
Less: accumulated amortization	(9,020)		(9,020)
Total trademarks	145,353		109,914
Total intangible assets	$	33,655,099	$	21,444,545

Goodwill	$	784,000	$	—

Schedule of expected amortization expense of intangible assets

Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:


	2018		2017		2016

Amortization expense	$	2,769,466	$	2,436,222	$	2,194,039

The expected amortization expense for the Company's current balance of intangible assets are as follows:


Year ending December 31:
2019	$	3,658,612
2020	3,737,638
2021	3,737,638
2022	3,426,180
2023 and thereafter	19,095,031
	$	33,655,099

Earnings (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Schedule of calculation of numerator and denominator in earnings per share

The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:


	2018		2017		2016

Numerator:
Net income (loss) attributable to common shareholders	$	(6,963,068)	$	(7,978,633)	$	(944,683)

Denominator:
Weighted-average shares outstanding – basic	15,614,052		15,911,577		16,236,525
Dilutive effect of restricted stock and stock options	—		—		—
Weighted-average shares outstanding – diluted	15,614,052		15,911,577		16,236,525

Schedule of anti-dilutive securities excluded from computation of earnings per share

The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:


	2018	2017	2016

Anti-dilutive shares and options	41,650	18,325	13,300

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of deferred tax assets and liabilities, net

The components of the Company's net deferred tax assets at December 31 are as follows:


	2018		2017

Deferred Tax Assets
Net operating loss and tax credits	$	16,410,403	$	15,295,547
Property and equipment and intangibles	236,318		232,667
Allowance for accounts receivable	251,068		129,180
Reserve for expired product	558,484		538,141
Inventory	193,150		173,885
Deferred charges	910,577		624,367
Cumulative compensation costs incurred on deductible equity awards	884,049		793,206
Total deferred tax assets	19,444,049		17,786,993

Deferred Tax Liabilities
Intangible assets	(1,974,787)		(2,067,548)
Net deferred tax assets, before valuation allowance	17,469,262		15,719,445
Less: deferred tax asset valuation allowance	(17,382,052)		(15,632,235)
Net deferred tax assets	$	87,210	$	87,210

Schedule of federal and state net operating loss carryforwards

The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December 31, 2018:


Years of expiration	Federal		State

2019	$	—	$	238,047
2020 - 2028	—		38,886,662
2029	44,153,819		10,508,184
2030 - 2037	7,534,351		9,617,093
Indefinite Period	3,918,317		137,040

Total federal and state net operating loss carryforwards	$	55,606,487	$	59,387,026

Schedule of the components of income tax benefit (expense)

Income tax (expense) benefit includes the following components for the years ended December 31:


	2018		2017		2016

Current:
Federal	$	—	$	—	$	867,041
State and other	(16,636)		(59,243)		83,463
Total current income tax (expense) benefit	(16,636)		(59,243)		950,504

Deferred:
Federal	—		(3,682,772)		(537,965)
State	—		(432,874)		(81,615)
Total deferred income tax (expense) benefit	—		(4,115,646)		(619,580)
Total income tax (expense) benefit	$	(16,636)	$	(4,174,889)	$	330,924

Schedule of effective tax rate reconciliation

The Company’s effective income tax rate for 2018, 2017 and 2016 reconciles with the federal statutory tax rate as follows:


	2018		2017		2016

Federal tax expense at statutory rate	21	%	34	%	34	%
State income tax expense (net of federal income tax benefit)	4	%	4	%	4	%
Permanent differences associated with general business credits	1	%	1	%	5	%
Change in valuation allowance	(25)	%	(148)	%	(15)	%
Change in tax rate	—	%	2	%	—	%
Other permanent differences	(1)	%	1	%	(2)	%
Other	—	%	(2)	%	(1)	%
Net income tax expense	—	%	(108)	%	25	%

Stock-Based Compensation Plans (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of share-based compensation expense

Stock compensation expense consisted of the following for the years ended December 31:


	2018		2017		2016

Share-based compensation - employees	$	1,244,606	$	1,032,094	$	833,027
Share-based compensation - nonemployees	120,092		82,969		19,075
Share-based compensation - foundation contribution	$	—	$	372,500	$	—
Total share-based compensation	$	1,364,698	$	1,487,563	$	852,102

Schedule of stock options activity

Stock option activity for 2018 and 2017 was as follows:


	Number of shares	Weighted-average exercise price per share		Weighted- average remaining contractual term (years)	Aggregate intrinsic value

Outstanding, December 31, 2016	5,800	$	13.00	1.9	$	—
Options granted	—	—
Options exercised	—	—
Options forfeited or expired	—	—
Outstanding, December 31, 2017	5,800	13.00		0.9	—
Options granted	—	—
Options exercised	—	—
Options forfeited or expired	—	—
Outstanding, December 31, 2018	5,800	13.00		0.1	—
Exercisable at December 31, 2018	5,800	$	13.00	0.1	$	—

Schedule of stock options activity, additional disclosures

Information related to the stock option plans during 2018, 2017 and 2016 was as follows:


	2018		2017		2016

Intrinsic value of options exercised	$	—	$	—	$	—
Weighted-average fair value of options exercised	$	—	$	—	$	—

Schedule of restricted stock activity

Restricted stock activity was as follows:


	Number of shares	Weighted- average grant-date fair value

Nonvested, December 31, 2016	703,295	$	5.13
Shares granted	238,550	6.48
Shares vested	(146,275)	4.74
Shares forfeited	(27,725)	5.34
Nonvested, December 31, 2017	767,845	5.61
Shares granted	261,680	6.66
Shares vested	(170,759)	4.79
Shares forfeited	(25,025)	6.19
Nonvested, December 31, 2018	833,741	$	6.09

Leases (Tables)

12 Months Ended

Dec. 31, 2018

Leases [Abstract]

Schedule of rent expense and sublease income

Rent expense and sublease income were as follows for the years ended December 31:


	2018		2017		2016

Rent expense	$	1,136,610	$	1,074,437	$	1,150,614

Sublease income	$	662,358	$	573,494	$	646,235

Schedule of future minimum lease payments for operating leases

Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:


Year ending December 31:
2019	$	959,902
2020	980,720
2021	1,001,603
2022	871,969
2023	44,508
2024 and thereafter	—
Total future minimum lease payments	$	3,858,702

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2018

Fair Value Disclosures [Abstract]

Schedule of fair value of financial instruments by level in hierarchy

The following table summarizes the fair value of these marketable securities by level within the fair value hierarchy:


	December 31, 2018										December 31, 2017
	Level 1		Level 2		Total		Level 1		Level 2		Total

U.S. Treasury notes and bonds	$	5,034,955	$	—	$	5,034,955	$	—	$	—	$	—
U.S. Agency issued mortgage-backed securities - variable rate	—		—		—		—		3,539,102		3,539,102
U.S. Agency notes and bonds - fixed rate	—		—		—		—		198,293		198,293
Corporate bonds	—		2,504,551		2,504,551
SBA loan pools - variable rate	—		—		—		—		935,081		935,081
Short-term cash investments	—		751,173		751,173		—		—		—
Total fair value of marketable securities	$	5,034,955	$	3,255,724	$	8,290,679	$	—	$	4,672,476	$	4,672,476

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Market Concentrations (Tables)

12 Months Ended

Dec. 31, 2018

Risks and Uncertainties [Abstract]

Schedule of revenues concentration from major customers

Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31:


	2018	2017	2016

Customer 1	26%	25%	22%
Customer 2	24%	22%	28%
Customer 3	25%	25%	29%
Customer 4	*%	*%	10%
Customer 5	11%	*%	*%
*: less than 10% of total

Quarterly Financial Information (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Schedule of quarterly financial information

The following table sets forth the unaudited operating results for each fiscal quarter of 2018 and 2017:


	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total

2018:
Net revenues	$	8,587,605	$	10,163,724	$	8,492,530	$	13,497,906	$	40,741,765
Operating income (loss)	(2,452,222)		(868,978)		(1,806,883)		(2,262,689)		(7,390,772)
Net income (loss) attributable to common shareholders	(2,379,239)		(720,688)		(1,643,044)		(2,220,097)		(6,963,068)
Earnings (loss) per share attributable to common shareholders ⁽¹⁾
Basic	$	(0.15)	$	(0.05)	$	(0.11)	$	(0.14)	$	(0.45)
Diluted	$	(0.15)	$	(0.05)	$	(0.11)	$	(0.14)	$	(0.45)

2017:
Net revenues	$	9,636,755	$	8,667,127	$	11,196,961	$	11,649,288	$	41,150,131
Operating income (loss)	(657,802)		(1,680,871)		(839,349)		(903,326)		(4,081,348)
Net income (loss) attributable to common shareholders	(1,274,446)		(5,160,611)		(743,031)		(800,545)		(7,978,633)
Earnings (loss) per share attributable to common shareholders ⁽¹⁾
Basic	$	(0.08)	$	(0.32)	$	(0.05)	$	(0.05)	$	(0.50)
Diluted	$	(0.08)	$	(0.32)	$	(0.05)	$	(0.05)	$	(0.50)

(1) Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.

Organization (Narrative) (Details) - USD ($)	12 Months Ended
Organization (Narrative) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2015
Noncontrolling Interest [Abstract]
Noncontrolling interest, ownership percentage by parent				85.00%
Exercise of options and related tax benefit			$ 1,000,000
Net loss at subsidiary allocated to noncontrolling interests	$ 75,704	$ 71,182	$ 59,255
Cumberland Emerging Technologies, Inc (CET)
Noncontrolling Interest [Abstract]
Noncontrolling interest, ownership percentage by parent	80.00%
Cumberland Emerging Technologies, Inc (CET) \| Harbin Gloria Pharmaceuticals Co
Noncontrolling Interest [Abstract]
Exercise of options and related tax benefit	$ 1,000,000.0

Significant Accounting Policies (Narrative) (Details)	3 Months Ended								12 Months Ended
Significant Accounting Policies (Narrative) (Details)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2018 USD ($) segment	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jan. 01, 2019 USD ($)
Segment Reporting [Abstract]
Number of operating segments \| segment									1
Net revenues from customers outside the United States	$ 13,497,906	$ 8,492,530	$ 10,163,724	$ 8,587,605	$ 11,649,288	$ 11,196,961	$ 8,667,127	$ 9,636,755	$ 40,741,765	$ 41,150,131	$ 33,025,560
Distribution costs									618,756	621,142	703,353
Advertising costs									2,219,074	2,589,185	2,626,238
Accounting Standards Update 2016-02 \| Scenario, Forecast \| Subsequent Event \| Minimum
Segment Reporting [Abstract]
ROU asset												$ 3,600,000
Lease liabilities												3,600,000
Accounting Standards Update 2016-02 \| Scenario, Forecast \| Subsequent Event \| Maximum
Segment Reporting [Abstract]
ROU asset												4,200,000
Lease liabilities												$ 4,200,000
Non-US
Segment Reporting [Abstract]
Net revenues from customers outside the United States									$ 2,100,000	$ 1,600,000	$ 2,000,000.0

Omeclamox®-Pak, Ethyol®, RediTrex®, Totect® and Vibativ® - Narrative (Details) - USD ($) shares in Thousands		1 Months Ended	12 Months Ended
	Oct. 29, 2013	Nov. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Payments for asset acquisitions			$ 2,300,000
Revenue from Contract with Customer, Excluding Assessed Tax			40,200,832	$ 40,376,563	$ 32,478,185
Other revenue, potential upfront payment related to product sales			4,600,000
Payments to acquire businesses			20,000,000	0	0
Amended International Agreement \| Pernix Therapeutics
Business Acquisition [Line Items]
Other revenue, potential upfront payment related to product sales	$ 4,000,000.0		2,300,000
Omeclamox-Pak
Business Acquisition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax			600,000	1,800,000
Ethyol \| Minimum
Business Acquisition [Line Items]
Royalty payments based on percentage over gross profits	30.00%
Ethyol \| Maximum
Business Acquisition [Line Items]
Royalty payments based on percentage over gross profits	50.00%
Methotrexate
Business Acquisition [Line Items]
Payments to acquire businesses		$ 100,000
Liabilities incurred		$ 900,000
Stock issued during period, acquisitions			1,100,000	1,300,000
Omeclamox-Pak
Business Acquisition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax			623,297	1,761,868	2,536,027
Ethyol
Business Acquisition [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax			$ 10,545,906	$ 10,835,038	$ 838,386
Restricted Stock \| Methotrexate
Business Acquisition [Line Items]
Stock issued during period, acquisitions (in shares)		180

Omeclamox®-Pak, Ethyol®, RediTrex®, Totect® and Vibativ® - Vibativ Acquisition - Narrative (Details) - USD ($)		1 Months Ended	12 Months Ended
	Mar. 08, 2019	Nov. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Payments to acquire businesses			$ 20,000,000	$ 0	$ 0
VIBATIV
Business Acquisition [Line Items]
Payments to acquire businesses		$ 20,000,000.0	20,000,000
Additional payments to acquire businesses			5,000,000
Tiered royalty payments (percentage)		20.00%
Revenue contributed			$ 5,100,000
VIBATIV \| Subsequent Event
Business Acquisition [Line Items]
Additional payments to acquire businesses	$ 5,000,000.0

Omeclamox®-Pak, Ethyol®, RediTrex®, Totect® and Vibativ® - Vibativ Acquisition - Schedule of Contingent Consideration and Preliminary Allocation (Details) - USD ($)	1 Months Ended	2 Months Ended		12 Months Ended
	Nov. 30, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Cash paid at closing				$ 20,000,000	$ 0	$ 0
Goodwill		$ 784,000	$ 784,000	784,000	$ 0
VIBATIV
Business Acquisition [Line Items]
Cash paid at closing	$ 20,000,000.0			20,000,000
Cash payment during early 2019				5,000,000
Fair value of contingent consideration - net sales royalty				9,034,000
Total consideration				34,034,000
Balance at November 12, 2018		9,034,000
Change in fair value of contingent consideration included in operating expenses		(40,000)
Contingent consideration earned and accrued in operating expenses			508,000
Balance at December 31, 2018		$ 9,502,000	$ 9,502,000	$ 9,502,000
Finished goods inventory	6,624,000
Work in process - unlabeled vials	3,970,000
Work in process - validation vials	1,827,000
Raw materials	9,129,000
Total inventory	21,550,000
Intellectual property amortizable intangible assets	11,700,000
Goodwill	784,000
Total intangibles and goodwill	12,484,000
Total assets acquired	$ 34,034,000

Revenues (Schedule of Net Product Revenues by Product) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue from External Customer [Line Items]
Revenues	$ 40,200,832	$ 40,376,563	$ 32,478,185
Acetadote
Revenue from External Customer [Line Items]
Revenues	4,284,111	6,576,720	7,214,341
Omeclamox-Pak
Revenue from External Customer [Line Items]
Revenues	623,297	1,761,868	2,536,027
Kristalose
Revenue from External Customer [Line Items]
Revenues	12,055,625	11,455,805	15,898,760
Vaprisol
Revenue from External Customer [Line Items]
Revenues	1,763,874	1,576,222	1,857,838
Caldolor
Revenue from External Customer [Line Items]
Revenues	5,001,997	4,178,443	4,132,833
Ethyol
Revenue from External Customer [Line Items]
Revenues	10,545,906	10,835,038	838,386
Totect
Revenue from External Customer [Line Items]
Revenues	850,965	3,992,467	0
Vibativ
Revenue from External Customer [Line Items]
Revenues	$ 5,075,057	$ 0	$ 0

Revenues (Narrative) (Details) - USD ($)	12 Months Ended
Revenues (Narrative) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Product Revenues
Revenues	$ 40,200,832	$ 40,376,563	$ 32,478,185
Accrued liabilities, current	16,710,927	8,714,814
Other Revenues
Other revenue, upfront payment	1,500,000
Other revenue, potential upfront payments related to regulatory approval	2,400,000
Other revenue, potential upfront payment related to product sales	4,600,000
Cumulative upfront payment	1,500,000
Milestone payments associated with international agreements	100,000
Product Sales Related Accruals - Rebates, Product Returns, Administrative Fees and Service Fees
Product Revenues
Accrued liabilities, current	5,600,000	4,700,000
Caldolor
Product Revenues
Revenues	5,001,997	4,178,443	4,132,833
Product, Acetadote, Generic
Product Revenues
Revenues	3,100,000	4,600,000	4,800,000
Ethyol
Product Revenues
Revenues	10,545,906	10,835,038	838,386
Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods
Product Revenues
Accounts receivable, allowances, current	900,000	500,000
Collaborative Arrangement, Federal Small Business Grant Programs \| Grant
Product Revenues
Revenues	$ 100,000	$ 200,000	$ 100,000

Inventories (Schedule of Inventories) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials and work in process	$ 18,378,450	$ 3,156,002
Consigned inventory	937,006	249,964
Finished goods, net of reserve	8,511,887	3,331,882
Total inventories	27,827,343	6,737,848
less non-current inventories	(15,749,000)	0
Total inventories	$ 12,078,343	$ 6,737,848

Inventories (Narrative) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Inventory reserves, obsolescence and discontinuance	$ 300,000	$ 200,000
Inventory, Noncurrent	15,749,000	$ 0
VIBATIV
Inventory [Line Items]
Inventory, Noncurrent	$ 800,000

Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,895,923	$ 3,440,354
Less: accumulated depreciation and amortization	(3,124,710)	(2,911,472)
Total property and equipment, net	771,213	528,882
Computer Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,148,140	1,074,172
Computer Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Computer Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Office Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 809,153	457,945
Office Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Office Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	15 years
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 639,267	633,577
Furniture and Fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Furniture and Fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	15 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,299,363	$ 1,274,660
Property and equipment, useful life (Textual)	3 – 15 years, or remaining lease term
Leasehold Improvements \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Leasehold Improvements \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	15 years

Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$ 33,655,099	$ 21,444,545
Product and License Rights
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	36,573,941	21,879,981
Accumulated amortization	(8,405,188)	(6,564,007)
Intangible assets, net	28,168,753	15,315,974
Patents
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	9,428,266	9,177,647
Accumulated amortization	(4,087,273)	(3,158,990)
Intangible assets, net	5,340,993	6,018,657
Trademarks
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	154,373	118,934
Accumulated amortization	(9,020)	(9,020)
Intangible assets, net	$ 145,353	$ 109,914

Intangible Assets (Narrative) (Details) - USD ($) shares in Thousands		1 Months Ended		12 Months Ended
	Oct. 29, 2013	Nov. 30, 2018	Nov. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Feb. 28, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Other revenue, potential upfront payment related to product sales				$ 4,600,000
Additions to intangible assets				3,819,486	$ 1,213,110	$ 2,000,226
Payments to acquire businesses				20,000,000	0	0
Goodwill				784,000	0
Amortization of intangible assets				2,769,466	2,436,222	$ 2,194,039
Product and License Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross				36,573,941	21,879,981
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross				9,428,266	9,177,647
Additions to intangible assets				400,000	400,000
Vaprisol \| Product and License Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross							$ 3,000,000.0
Pernix Therapeutics \| Collaborative Arrangement, Amended International Agreement
Acquired Finite-Lived Intangible Assets [Line Items]
Other revenue, potential upfront payment related to product sales	$ 4,000,000.0			2,300,000
Methotrexate
Acquired Finite-Lived Intangible Assets [Line Items]
Payments to acquire businesses			$ 100,000
Stock issued during period, acquisitions				1,100,000	$ 1,300,000
VIBATIV
Acquired Finite-Lived Intangible Assets [Line Items]
Payments to acquire businesses		$ 20,000,000.0		$ 20,000,000
Intellectual property amortizable intangible assets		11,700,000
Goodwill		$ 784,000
Restricted Stock \| Methotrexate
Acquired Finite-Lived Intangible Assets [Line Items]
Stock issued during period, acquisitions (in shares)			180

Intangible Assets Future Amortization Expense (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
2018	$ 3,658,612
2019	3,737,638
2020	3,737,638
2021	3,426,180
2022 and thereafter	19,095,031
Intangible assets, net	$ 33,655,099	$ 21,444,545

Other Current and Other Long-term Liabilities (Schedule of Other Current and Noncurrent Liabilities) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Other Liabilities, Current [Abstract]
Rebates, product returns, administrative fees and service fees	$ 5,635,972	$ 4,683,694
Employee wages and benefits	1,263,426	1,032,652
Stock payable	1,085,400	1,324,800
Current portion of accrued contingent consideration	2,290,000	0
Deferred acquisition liability	5,000,000	0
Accrued inventory purchases	434,405	1,055,220
Other	1,001,724	618,448
Total other current liabilities	16,710,927	8,714,814
Noncurrent portion of accrued contingent consideration	7,212,000	0
Deferred compensation	1,588,123	1,599,960
Other	519,020	216,008
Other Liabilities, Noncurrent, Total	$ 9,319,143	$ 1,815,968

Debt (Line of Credit) (Details) - USD ($)	Jul. 31, 2017	Dec. 31, 2018	Oct. 17, 2018	Dec. 31, 2017
Line of Credit Facility [Line Items]
Revolving line of credit		$ 20,000,000		$ 9,800,000
Pinnacle Bank \| Second Amendment \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity			$ 20,000,000.0
Revolving line of credit		20,000,000.0
Pinnacle Bank \| Line of Credit \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit, maximum borrowing capacity		12,000,000.0
Line of credit, maximum borrowing capacity upon satisfaction of certain conditions		$ 20,000,000.0
Revolving line of credit				$ 9,800,000
Interest rate		4.30%
Line of credit, unused capacity, commitment fee percentage	0.25%
Pinnacle Bank \| Line of Credit \| Revolving Credit Facility \| Minimum
Line of Credit Facility [Line Items]
Interest rate		1.75%
Pinnacle Bank \| Line of Credit \| Revolving Credit Facility \| Maximum
Line of Credit Facility [Line Items]
Interest rate		2.75%

Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)		1 Months Ended	12 Months Ended
	Aug. 10, 2009 USD ($) $ / shares shares	Jan. 31, 2018 USD ($)	Dec. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares
Initial Public Offering [Abstract]
Initial public offering, issuance costs			$ 383,310	$ 27,950	$ 0
Preferred Stock [Abstract]
Preferred stock, shares authorized \| shares			20,000,000
Common Stock [Abstract]
Shelf Registration, sale of corporate securities (up to)		$ 100,000,000
Common stock
Initial Public Offering [Abstract]
Initial public offering, effective date	Aug. 10, 2009
Initial public offering, shares issued \| shares	5,000,000
Initial public offering, price per share \| $ / shares	$ 17.00
Initial public offering, gross proceeds	$ 85,000,000.0
Initial public offering, underwriting discounts	6,000,000.0
Initial public offering, issuance costs	4,200,000
Initial public offering, net proceeds	$ 74,800,000
Initial public offering, number of shares common stock received in exchange for preferred stock	2,000,000
Common stock
Initial Public Offering [Abstract]
Initial public offering, shares issued \| shares			30,704
Common Stock [Abstract]
Share-based compensation, shares \| shares			170,759	146,275	223,987
Exercise of options and related tax benefit, shares \| shares					3,409

Shareholders' Equity (Warrants, Narrative) (Details) - $ / shares	Dec. 31, 2009	Dec. 31, 2006
Warrants, Issued in Consideration of 2006 Credit Facility Amendment
Class of Warrant or Right [Line Items]
Warrants, number of shares called by warrants		3,958
Warrants, exercise price		$ 9.00
Warrants, Issued in Consideration of 2009 Credit Facility Amendment
Class of Warrant or Right [Line Items]
Warrants, number of shares called by warrants	7,500
Warrants, exercise price	$ 17.00

Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2014	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2015	May 31, 2010
Equity, Class of Treasury Stock [Line Items]
Repurchase of common shares, value		$ 2,877,935	$ 3,719,890	$ 2,520,715
Exercise of options and related tax benefit				$ 1,000,000
Noncontrolling interest, ownership percentage by parent					85.00%
Payments to acquire interest in subsidiaries	$ 1,000,000.0
Loans Forgiven in Exchange For Share Issued, Amount	$ 2,400,000
Common stock
Equity, Class of Treasury Stock [Line Items]
Repurchase of common shares, shares		443,041	547,376	529,312
Repurchase of common shares, value		$ 2,877,935	$ 3,719,890	$ 2,520,715
Charitable contribution of shares, shares			50,000
Cumberland Emerging Technologies, Inc (CET)
Equity, Class of Treasury Stock [Line Items]
Noncontrolling interest, ownership percentage by parent		80.00%
Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options
Equity, Class of Treasury Stock [Line Items]
Repurchase of common shares, shares		443,041	547,376	529,312
Repurchase of common shares, value		$ 2,900,000	$ 3,700,000	$ 2,500,000
Share Repurchase Program Authorized in 2010
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized to be repurchased						$ 10,000,000

Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net income (loss) attributable to common shareholders	$ (2,220,097)	$ (1,643,044)	$ (720,688)	$ (2,379,239)	$ (800,545)	$ (743,031)	$ (5,160,611)	$ (1,274,446)	$ (6,963,068)	$ (7,978,633)	$ (944,683)
Denominator:
Weighted-average shares outstanding – basic (in shares)									15,614,052	15,911,577	16,236,525
Dilutive effect of restricted stock and stock options (in shares)									0	0	0
Weighted-average shares outstanding – diluted (in shares)									15,614,052	15,911,577	16,236,525

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Income Taxes (Operating Loss Carryforwards, Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2018
Operating Loss Carryforwards [Line Items]
Cumulative effect from change in accounting principle (Note 12)		$ 1,082,924
Deferred tax asset, net of related valuation allowance				$ 17,000,000.0
Valuation allowance	$ 17,382,052	15,632,235		15,900,000
Net tax benefit		100,000
Valuation allowance for deferred tax assets:
Operating Loss Carryforwards [Line Items]
Charged to costs and expenses	1,749,817	(665,039)	$ 203,003
Retained earnings
Operating Loss Carryforwards [Line Items]
Cumulative effect from change in accounting principle (Note 12)		$ 1,082,924
Retained earnings \| Accounting Standards Update 2016-09
Operating Loss Carryforwards [Line Items]
Cumulative effect from change in accounting principle (Note 12)				1,100,000
Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	55,606,487
State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 59,387,026
Exercise of NonQualified Stock Options \| Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards				$ 44,100,000

Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details) - USD ($)	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Deferred Tax Assets
Net operating loss and tax credits	$ 16,410,403		$ 15,295,547
Property and equipment and intangibles	236,318		232,667
Allowance for accounts receivable	251,068		129,180
Reserve for expired product	558,484		538,141
Inventory	193,150		173,885
Deferred charges	910,577		624,367
Cumulative compensation costs incurred on deductible equity awards	884,049		793,206
Total deferred tax assets	19,444,049		17,786,993
Deferred Tax Liabilities
Intangible assets	(1,974,787)		(2,067,548)
Net deferred tax assets, before valuation allowance	17,469,262		15,719,445
Less: deferred tax asset valuation allowance	(17,382,052)	$ (15,900,000)	(15,632,235)
Net deferred tax assets	$ 87,210		$ 87,210

Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)	Dec. 31, 2018 USD ($)
Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 55,606,487
State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	59,387,026
Expiration from 2018-2019 \| Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	0
Expiration from 2018-2019 \| State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	238,047
Expiration from 2020 to 2028 \| Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	0
Expiration from 2020 to 2028 \| State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	38,886,662
Expiration from in 2029 \| Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	44,153,819
Expiration from in 2029 \| State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	10,508,184
Expiration from 2030 to 2037 \| Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	7,534,351
Expiration from 2030 to 2037 \| State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	9,617,093
Indefinite Period \| Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	3,918,317
Indefinite Period \| State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 137,040

Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current:
Federal	$ 0	$ 0	$ 867,041
State and other	(16,636)	(59,243)	83,463
Total current income tax (expense) benefit	(16,636)	(59,243)	950,504
Deferred:
Federal	0	(3,682,772)	(537,965)
State	0	(432,874)	(81,615)
Deferred income tax (expense) benefit	0	(4,115,646)	(619,580)
Total income tax (expense) benefit	$ (16,636)	$ (4,174,889)	$ 330,924

Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Federal tax expense at statutory rate	21.00%	34.00%	34.00%
State income tax expense (net of federal income tax benefit)	4.00%	4.00%	4.00%
Permanent differences associated with general business credits	1.00%	1.00%	5.00%
Change in valuation allowance	(25.00%)	(148.00%)	(15.00%)
Change in tax rate	0	0.02	0
Other permanent differences	(1.00%)	1.00%	(2.00%)
Other	0.00%	(2.00%)	(1.00%)
Net income tax expense	0.00%	(108.00%)	25.00%

Stock-Based Compensation Plans (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($) plan shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity compensation plans available for future grants \| plan	2
Unrecognized compensation cost related to share-based payments \| $	$ 2.4
Unrecognized compensation cost related to share-based payments, period for recognition	2 years 7 months 6 days
NonPrincipal Owner
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, exercise price as percent of weighted-average grant date fair value	100.00%
Long-Term Incentive Compensation Plan 2007
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance under equity compensation plans	2,400,000
Directors’ Incentive Plan 2007
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for issuance under equity compensation plans	250,000
Stock Options \| Principal Owner
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period	5 years
Stock Options \| NonPrincipal Owner \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period	10 years
Restricted Stock \| Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Restricted Stock \| Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year

Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 1,364,698	$ 1,115,063	$ 852,102
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	1,244,606	1,032,094	833,027
Nonemployee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	120,092	82,969	19,075
Foundation Contribution
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	0	372,500	0
Employee, Nonemployee and Foundation Contribution
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 1,364,698	$ 1,487,563	$ 852,102

Stock-Based Compensation Plans (Schedule of Stock Options Activity) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of shares
Outstanding, beginning of period, shares	5,800	5,800
Options granted, shares	0	0
Options exercised, shares	0	0
Options forfeited or expired, shares	0	0
Outstanding, end of period, shares	5,800	5,800	5,800
Options, exerciseable, end of period, shares	5,800
Weighted-average exercise price per share
Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)	$ 13.00	$ 13.00
Options granted, weighted-average exercise price per share (in USD per share)	0	0
Options exercised, weighted-average exercise price per share (in USD per share)	0	0
Options forfeited or expired, weighted-average exercise price per share (in USD per share)	0	0
Outstanding, end of period, weighted-average exercise price per share (in USD per share)	13.00	$ 13.00	$ 13.00
Exercisable, end of period, weighted-average exercise price per share (in USD per share)	$ 13.00
Outstanding, end of period, weighted-average remaining contractual term	1 month 6 days	10 months 24 days	1 year 10 months 24 days
Exercisable, end of period, weighted-average remaining contractual term	1 month 6 days
Outstanding, end of period, aggregate intrinsic value	$ 0	$ 0	$ 0
Exercisable, end of period, aggregate intrinsic value	$ 0

Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details) - Restricted Stock - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of shares
Nonvested, beginning of period, shares	767,845	703,295
Shares granted, shares	261,680	238,550
Shares vested, shares	(170,759)	(146,275)
Shares forfeited, shares	(25,025)	(27,725)
Nonvested, end of period, shares	833,741	767,845
Weighted- average grant-date fair value
Nonvested, beginning of period, weighted-average grant-date fair value	$ 5.61	$ 5.13
Shares granted, weighted-average grant-date fair value	6.66	6.48
Shares vested, weighted-average grant-date fair value	4.79	4.74
Shares forfeited, weighted-average grant-date fair value	6.19	5.34
Nonvested, end of period, weighted-average grant-date fair value	$ 6.09	$ 5.61

Employee Benefit Plans (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Contribution Plan [Abstract]
Defined contribution plan, eligibiilty, minimum employee age	21 years
Defined contribution plan, eligibility, minimum employee service time for participation eligibility	six months
Defined contribution plan, employer discretionary contribution amount	$ 50	$ 50	$ 50
Deferred Compensation Arrangements [Abstract]
Deferred compensation liability	1,600
Deferred compensation assets	$ 2,300

Leases (Schedule of Rent Expense and Sublease Income) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Leases [Abstract]
Rent expense	$ 1,136,610	$ 1,074,437	$ 1,150,614
Sublease income	662,358	$ 573,494	$ 646,235
Future minimum sublease income under noncancelable operating subleases	$ 300,000

Leases (Schedule of Future Minimum Rental Payments for Operating Leases) (Details)	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 959,902
2020	980,720
2021	1,001,603
2022	871,969
2023	44,508
2024 and thereafter	0
Total future minimum lease payments	$ 3,858,702

Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Sales Revenue, Goods, Gross \| Customer 1
Concentration Risk [Line Items]
Concentration risk, percentage	26.00%	25.00%	22.00%
Sales Revenue, Goods, Gross \| Customer 2
Concentration Risk [Line Items]
Concentration risk, percentage	24.00%	22.00%	28.00%
Sales Revenue, Goods, Gross \| Customer 3
Concentration Risk [Line Items]
Concentration risk, percentage	25.00%	25.00%	29.00%
Sales Revenue, Goods, Gross \| Customer 4
Concentration Risk [Line Items]
Concentration risk, percentage			10.00%
Sales Revenue, Goods, Gross \| Customer 5
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%
Accounts Receivable
Concentration Risk [Line Items]
Concentration risk, percentage	78.00%	53.00%

Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 13,497,906	$ 8,492,530	$ 10,163,724	$ 8,587,605	$ 11,649,288	$ 11,196,961	$ 8,667,127	$ 9,636,755	$ 40,741,765	$ 41,150,131	$ 33,025,560
Operating income (loss)	(2,262,689)	(1,806,883)	(868,978)	(2,452,222)	(903,326)	(839,349)	(1,680,871)	(657,802)	(7,390,772)	(4,081,348)	(1,433,131)
Net income (loss) attributable to common shareholders	$ (2,220,097)	$ (1,643,044)	$ (720,688)	$ (2,379,239)	$ (800,545)	$ (743,031)	$ (5,160,611)	$ (1,274,446)	$ (6,963,068)	$ (7,978,633)	$ (944,683)
Earnings per share attributable to common shareholders
Basic (in USD per share)	$ (0.14)	$ (0.11)	$ (0.05)	$ (0.15)	$ (0.05)	$ (0.05)	$ (0.32)	$ (0.08)	$ (0.45)	$ (0.50)	$ (0.06)
Diluted (in USD per share)	$ (0.14)	$ (0.11)	$ (0.05)	$ (0.15)	$ (0.05)	$ (0.05)	$ (0.32)	$ (0.08)	$ (0.45)	$ (0.50)	$ (0.06)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Valuation and Qualifying Accounts (Details) - USD ($)	12 Months Ended
Valuation and Qualifying Accounts (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Increase in valuation allowance during the year		$ 4,202,854
Revaluation of deferred income tax balances for new rates under TCJA		4,867,893
Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 507,534	449,859	$ 381,240
Charged to costs and expenses	6,286,581	5,066,526	3,755,804
Charged to other accounts	0	0	0
Deductions	(5,800,775)	(5,008,851)	(3,687,185)
Balance at end of period	993,340	507,534	449,859
Valuation allowance for deferred tax assets:
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	15,632,235	388,500	185,497
Charged to costs and expenses	1,749,817	(665,039)	203,003
Charged to other accounts	0	15,908,774	0
Deductions	0	0	0
Balance at end of period	$ 17,382,052	$ 15,632,235	$ 388,500

Manufacturing and Supply Agreements	12 Months Ended
Manufacturing and Supply Agreements	Dec. 31, 2018
Manufacturing and Supply Agreements [Abstract]
Manufacturing and Supply Agreements	Manufacturing and Supply AgreementsThe Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms. A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.

Employment Agreements	12 Months Ended
Employment Agreements	Dec. 31, 2018
Employment Agreements [Abstract]
Employment Agreements	Employment AgreementsThe Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock agreement.

Fair Value of Financial Instruments (Schedule of Fair Value of Financial Instruments by Level in Hierarchy and Narrative) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	$ 8,290,679	$ 4,672,476
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	5,034,955	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	3,255,724	4,672,476
U.S. Treasury notes and bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	5,034,955	0
U.S. Treasury notes and bonds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	5,034,955	0
U.S. Treasury notes and bonds \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	0
U.S. Agency issued mortgage-backed securities - variable rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	3,539,102
U.S. Agency issued mortgage-backed securities - variable rate \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	0
U.S. Agency issued mortgage-backed securities - variable rate \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	3,539,102
U.S. Agency notes and bonds - fixed rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	198,293
U.S. Agency notes and bonds - fixed rate \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	0
U.S. Agency notes and bonds - fixed rate \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	198,293
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	2,504,551
Corporate bonds \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0
Corporate bonds \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	2,504,551
SBA loan pools - variable rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	935,081
SBA loan pools - variable rate \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	0
SBA loan pools - variable rate \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	935,081
Short-term cash investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	751,173	0
Short-term cash investments \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	0	0
Short-term cash investments \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of marketable securities	$ 751,173	$ 0

Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)	Dec. 31, 2018 supplier
Minimum
Manufacturing and Supply Agreement [Line Items]
Manufacturing agreements, number of primary suppliers for each product	1
Maximum
Manufacturing and Supply Agreement [Line Items]
Manufacturing agreements, number of primary suppliers for each product	2

Commitments and Contingencies (Legal Matters, Narrative) (Details) - Acetadote - Patent Infringement	1 Months Ended
	Apr. 30, 2012 lawsuit company
Loss Contingencies [Line Items]
Number of lawsuits filed as plaintiff \| lawsuit	5
Number of companies for which litigation settlement exists \| company	2